Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Trophoblast Cell Surface Antigen 2”

16 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 16 of 16 results

Testing effectiveness (Phase 2)Looking for participantsNCT06953089
What this trial is testing

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

Who this might be right for
Solid Tumors
DualityBio Inc. 492
Not applicableLooking for participantsNCT06696326
What this trial is testing

Study Evaluating the Diagnostic Value of 68Ga-MY6349 PET/CT for Prostate Cancer

Who this might be right for
Positron-Emission Tomography(PET)Prostate CancerTrophoblast Cell Surface Antigen 2
The First Affiliated Hospital of Xiamen University 100
Not applicableLooking for participantsNCT07026110
What this trial is testing

Clinical Application Study of PET/CT for Differential Diagnosis of Non-small Cell Lung Cancer

Who this might be right for
Lung CancerLung DiseasesLung Neoplasms+2 more
RenJi Hospital 100
Not applicableLooking for participantsNCT06715839
What this trial is testing

Target-specific immunoPET Imaging of Digestive System Carcinoma

Who this might be right for
MalignancyDigestive CancerDigestive System Neoplasm+12 more
RenJi Hospital 400
Large-scale testing (Phase 3)Looking for participantsNCT06851663
What this trial is testing

Trop2-targeted immunoPET Imaging of Solid Tumors

Who this might be right for
Solid TumorSolid CarcinomaUroepithelial Carcinoma+11 more
RenJi Hospital 400
Not applicableStudy completedNCT06188468
What this trial is testing

ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Solid Tumors

Who this might be right for
TumorSolid TumorPositron-Emission Tomography
The First Affiliated Hospital of Xiamen University 90
Testing effectiveness (Phase 2)Looking for participantsNCT04559230
What this trial is testing

Sacituzumab Govitecan in Recurrent Glioblastoma

Who this might be right for
Recurrent Glioblastoma
The University of Texas Health Science Center at San Antonio 32
Large-scale testing (Phase 3)Looking for participantsNCT06841354
What this trial is testing

Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Who this might be right for
Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC 1,000
Testing effectiveness (Phase 2)Looking for participantsNCT06161532
What this trial is testing

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

Who this might be right for
Small Cell Carcinoma of the BladderSmall Cell Carcinoma of the Urinary TractSquamous Cell Carcinoma of the Bladder+5 more
National Cancer Institute (NCI)
Not applicableUnknownNCT03529604
What this trial is testing

Salivary Ap4A, SCCA, TROP2 in Oral Cancer Patients

Who this might be right for
Oral Cavity Squamous Cell CarcinomaSaliva AlteredPrecancerous Lesions
University of Zagreb 100
Large-scale testing (Phase 3)Looking for participantsNCT07216703
What this trial is testing

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Who this might be right for
Cervical Cancer
Merck Sharp & Dohme LLC 1,023
Large-scale testing (Phase 3)Looking for participantsNCT06952504
What this trial is testing

Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Who this might be right for
Endometrial Cancer
Merck Sharp & Dohme LLC 1,123
Not applicableEnded earlyNCT06465017
What this trial is testing

ImmunoPET Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) in Thyroid Cancer

Who this might be right for
TumorSolid TumorThyroid Cancer+1 more
The First Affiliated Hospital of Xiamen University 149
Large-scale testing (Phase 3)Looking for participantsNCT06074588
What this trial is testing

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC 556
Large-scale testing (Phase 3)Active Not RecruitingNCT06132958
What this trial is testing

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

Who this might be right for
Endometrial Cancer
Merck Sharp & Dohme LLC 710
Not applicableLooking for participantsNCT07177482
What this trial is testing

ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Craniopharyngioma Patients

Who this might be right for
Craniopharyngioma
Deling Li 20
60